Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Gemcitabine and Pemetrexed in Primary Unknown Adenocarcinoma

NCT00191503 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00191503
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00191503 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Gemcitabine and Pemetrexed in Primary Unknown Adenocarcinoma
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2005
Completion date
November 30, 2005
Enrollment
30
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma